Skip to content

Balance Acceptance and Commitment Therapy for Long COVID

A Randomised Controlled Trial Assessing the Efficacy of Balance Acceptance and Commitment Therapy (ACT) for Long COVID.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06231238
Acronym
BalanceACT
Enrollment
196
Registered
2024-01-30
Start date
2024-06-04
Completion date
2026-08-01
Last updated
2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long COVID, Post-COVID-19 Syndrome

Brief summary

This randomised controlled trial aims to investigate the efficacy of a psychological intervention for long COVID (LC) / post-COVID-19 syndrome (PCS) called Balance Acceptance and Commitment Therapy (Balance ACT). The primary objective of this trial is to investigate whether Balance-ACT improves quality of life over treatment as usual (i.e., self-help leaflet) in people with PCS/LC.

Interventions

BEHAVIORALBalance Acceptance and Commitment Therapy

Balance-ACT is an ACT-based psychological intervention specifically designed for people with PCS/LC. Balance-ACT will use ACT techniques and mindfulness and will focus on establishing a balance psychologically and physiologically and regulating homeostasis. More specifically, Balance ACT will aim to regulate behaviours such as sleep, stress and activity, which can subsequently have an impact on homeostasis and physiology. Balance-ACT will also encourage people to live a values-based life and set goals according to their values.

Sponsors

King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 18 or older 2. LC/PCS diagnosis as defined by National Health Service (NHS) / National Institute for Health and Care Excellence (NICE) (i.e., symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis). A checklist will be used to ensure participants fulfil the diagnostic criteria as per the NICE guidelines 3. Ability to travel to the research site for the study assessments 4. Having registered with a General Practitioner (GP) in the United Kingdom (UK) and consent to provide their details for the study team to contact 5. Ability to provide informed consent 6. Ability to read and write English

Exclusion criteria

1. Current diagnosis of an active major mental health disorder likely to interfere with participation 2. Unstable alcohol / drug dependency 3. Unstable complications associated with LC/PCS 4. Past hospitalisation for COVID-19 5. Current or recent participation in other treatment intervention studies (\<4 weeks after completion) 6. Currently receiving psychological support or psychotherapy 7. Pregnancy

Design outcomes

Primary

MeasureTime frame
Physical Component Summary (PCS) of the 36-item Short Form Health Survey (SF-36) at Week 14Week 14

Secondary

MeasureTime frameDescription
Lung function (spirometry, Resting pulse oximetry; SpO2)Week 0 and 14
Muscle strengthWeek 0, 7, 14 and 20Handgrip muscle strength: A handgrip dynamometer will be used to measure grip strength. The dynamometer will be placed in the participant's hand and the participant will be instructed to squeeze as hard as possible.
Muscle fatigueWeek 0 and 141. Handgrip volitional fatigue: A digital grip force transducer will be used to assess volitional handgrip fatigue. 2. Quadriceps non-volitional fatigue: Quadriceps muscle endurance will be assessed non-volitionally using transcutaneous electrical stimulation.
1 minute sit-to-stand testWeek 0 and 14Participants will also be shown the Borg Rating of Perceived Exertion Scale and asked to rate their perceived breathlessness and leg fatigue prior to the start of the test, immediately after completion of the test, and following one minute of recovery.
4 metre gait speedWeek 0 and 14
Short Physical Performance Battery (SPPB)Week 0 and 14
International Physical Activity Questionnaire - Short Form (IPAQ-SF)Week 0, 7, 14 and 20
Heartrate variabilityWeek 0 and 14via electrocardiogram (ECG)
Average Heart-rateWeek 0 and 14Average Heart-rate will be assessed from 5 minutes of a 10-minute resting 3 lead electrocardiogram (ECG). These short-term recordings provide a non-invasive measure of autonomic nervous system function.
Cognitive and Behavioural Responses Questionnaire (CBRQ)Week 0, 7, 14 and 20
Comprehensive assessment of Acceptance and Commitment Therapy processesWeek 0, 7, 14 and 20
Quadricep Muscle StrengthWeek 0 and 14Volitional Quadriceps MVC and assessment of quadriceps volitional activation by twitch interpolation using electrical stimulation.
Post COVID Syndrome Recovery (Single Item)Week 7, 14 and 20A self-reported single item questionnaire "Do you consider yourself recovered from long COVID?"
Treatment Satisfaction QuestionnaireWeek 14
Physical Component Summary (PCS) of the 36-item Short Form Health Survey (SF-36) at Week 20Week 0, 7, and 20
Mental Component Summary (MCS) of the 36-item Short Form Health Survey (SF-36)Week 0, 7, 14 and 20
EuroQol 5 Dimension - 5 Levels (EQ-5D-5L)Week 0, 14 and 20
Adult Service Use ScheduleWeek 0 and 20
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)Week 0, 7, 14 and 20
Modified Clinical Global Impressions Scale- Improvement (CGI-I)Week 14 and 20
Pittsburgh Sleep Quality Index (PSQI)Week 0, 7, 14 and 20
Modified Patient Health Questionnaire-15 (PHQ-15)Week 0, 7, 14 and 20
Montreal cognitive assessment-telephone version (MoCA-T)Week 0, 14 and 20
Perceived Deficits Questionnaire (PDQ)Week 0, 7, 14 and 20
Patient Health Questionnaire-8 (PHQ-8)Week 0, 7, 14 and 20
Generalised Anxiety Disorder-7 (GAD-7)Week 0, 7, 14 and 20
Work and social adjustment scale (WSAS)Week 0, 7, 14 and 20
Modified DePaul Post exertional malaise questionnaireWeek 0, 7, 14 and 20
Post Traumatic Stress Disorder Checklist for DSM 5 (PCL-5)Week 0, 14 and 20
Nijmegen Questionnaire (NQ)Week 0, 14 and 20
Modified Medical Research Council Dyspnea Scale (mMRC)Week 0, 14 and 20
Dyspnoea-12Week 0, 14 and 20

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026